Literature DB >> 31481003

Role of TREM2 in Alzheimer's Disease and its Consequences on β- Amyloid, Tau and Neurofibrillary Tangles.

Anurag K Singh1, Gaurav Mishra2, Anand Maurya2, Rajendra Awasthi3, Komal Kumari2, Abhimanyu Thakur4, Arati Rai5, Gopal Kumar Rai6, Bhupesh Sharma7, Giriraj T Kulkarni3, Santosh Kumar Singh1.   

Abstract

Alzheimer's Disease (AD) is age-related neurodegenerative disorder recognized by a steadily gradual cognitive decline that has devastating personal and socioeconomic implications. Recently, some genetic factors for AD have been identified which attracted wide attention of researchers in different areas of AD biology and possible new therapeutic targets. Alternative forms of triggering receptor expressed on myeloid cells 2 (TREM2) genes are examples of such risk factors, which contribute higher risk for developing AD. Comprehending TREM2 function pledge to provide salient insight into how neuroinflammation contributes to AD pathology. The dearth of microglial TREM2 shepherd to augmented tau pathology is couple with frequent enhancement of activated neuronal stress kinases. The involvement of TREM2 in the regulation of tau-associated innate immune response of the CNS has clearly demonstrated through these findings. However, whether decrease level of TREM2 assists pathology of tau through changed clearance and pathological escalation of tau or through direct contact between microglia and neuron and any alternative possible mechanisms need to examine. This review briefly summarizes distinct functional roles of TREM2 in AD pathology and highlights the TREM2 gene regulation. We have also addressed the impact of TREM2 on β-amyloid plaques and tau pathology in Alzheimer's disease. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Alzheimer’s disease; TREM2; microglia; neuronal degeneration; tau pathology; β-amyloid plaques.

Mesh:

Substances:

Year:  2019        PMID: 31481003     DOI: 10.2174/1567205016666190903102822

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  6 in total

Review 1.  Mesenchymal Stem Cell Therapy: A Potential Treatment Targeting Pathological Manifestations of Traumatic Brain Injury.

Authors:  Kaige Zhang; Yiming Jiang; Biyao Wang; Tiange Li; Dehao Shang; Xinwen Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-06-15       Impact factor: 7.310

Review 2.  Steroids and Alzheimer's Disease: Changes Associated with Pathology and Therapeutic Potential.

Authors:  Yvette Akwa
Journal:  Int J Mol Sci       Date:  2020-07-07       Impact factor: 5.923

3.  Discovery of Active Ingredients Targeted TREM2 by SPR Biosensor-UPLC/MS Recognition System, and Investigating the Mechanism of Anti-Neuroinflammatory Activity on the Lignin-Amides from Datura metel Seeds.

Authors:  Si-Yi Wang; Yan Liu; Xiao-Mao Li; Adnan Mohammed Algradi; Hai Jiang; Yan-Ping Sun; Wei Guan; Juan Pan; Hai-Xue Kuang; Bing-You Yang
Journal:  Molecules       Date:  2021-09-30       Impact factor: 4.411

Review 4.  Exploring the Paradox of COVID-19 in Neurological Complications with Emphasis on Parkinson's and Alzheimer's Disease.

Authors:  Sachchida Nand Rai; Neeraj Tiwari; Payal Singh; Anurag Kumar Singh; Divya Mishra; Mohd Imran; Snigdha Singh; Etrat Hooshmandi; Emanuel Vamanu; Santosh K Singh; Mohan P Singh
Journal:  Oxid Med Cell Longev       Date:  2022-08-31       Impact factor: 7.310

5.  The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease.

Authors:  So-Hee Park; Eun-Hye Lee; Hyung-Ji Kim; Sungyang Jo; Sunju Lee; Sang Won Seo; Hyun-Hee Park; Seong-Ho Koh; Jae-Hong Lee
Journal:  Sci Rep       Date:  2021-06-22       Impact factor: 4.379

6.  Microglia Implicated in Tauopathy in the Striatum of Neurodegenerative Disease Patients from Genotype to Phenotype.

Authors:  Huifangjie Li; William C Knight; Pengfei Yang; Yingqiu Guo; Joel S Perlmutter; John C Morris; Randall J Bateman; Tammie L S Benzinger; Jinbin Xu
Journal:  Int J Mol Sci       Date:  2020-08-22       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.